Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines

作者：Sebo Peter^*; Osicka Radim; Masin Jiri

来源：Expert Review of Vaccines, 2014, 13(10): 1215-1227.

DOI：10.1586/14760584.2014.944900

• adenylate cyclase toxin
• antigen delivery
• Bordetella pertussis
• cancer immunotherapy
• complement receptor 3
• dendritic cell
• pertussis
• pertussis vaccine
• T-cell epitope
• T-cell vaccine
• whooping cough

The adenylate cyclase toxin-hemolysin (ACT, AC-Hly or CyaA) is a key virulence factor of Bordetella pertussis. It targets bactericidal activities of phagocytes, such as oxidative burst and complement- or antibody-mediated opsonophagocytic killing of bacteria. Through cAMP signaling, CyaA also skews TLR-triggered maturation of dendritic cells, inhibiting proinflammatory IL-12 and TNF- secretion and enhancing IL-10 production and Treg expansion, likely hampering induction of adaptive immune responses to Bordetella infections. Non-enzymatic CyaA toxoid is a potent protective antigen and adjuvant that boosts immunogenicity of co-administered B. pertussis antigens and improves potency of acellular pertussis (aP) vaccines in mice. This makes CyaA a prime antigen candidate for inclusion into a next generation of aP vaccines. Moreover, recombinant CyaA toxoids were recently shown to be safe in humans in frame of Phase I clinical evaluation of a CyaA-based immunotherapeutic vaccine that induces Th1-polarized CD8(+) cytotoxic T-lymphocyte responses targeting cervical tumors.

• 出版日期2014-10